Top Markets
#1 QuantixAI QuantixAI +32.46%
#2 Siren Siren +30.35%
#3 MowCat MowCat +27.63%
#4 Prom Prom +20.98%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +19.43%
#6 Versatize Coin Versatize Coin +16.67%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +15.23%
#8 Tutorial Tutorial +15.03%
#9 UnifAI Network UnifAI Network +14.23%
#10 Wrapped NXM Wrapped NXM +11.45%
Coin of the day
QuantixAI QuantixAI
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Sunho Biologics, Inc. Sunho Biologics, Inc.

Sunho Biologics, Inc.

2898
Classifica tra le azioni #20675
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering,... Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby altering the immune microenvironment. Among its portfolio is IAH0968, a monoclonal antibody specifically engineered to enhance antibody-dependent cell-mediated cytotoxicity, currently undergoing Phase II clinical trials for the treatment of biliary tract carcinoma and colorectal cancer. The company also develops IAP0971 and IAE0972, a pair of immunocytokines that have successfully concluded Phase I clinical trials for various advanced solid tumors, notably non-small cell lung cancer and colorectal cancer. Sunho Biologics also boasts a robust pipeline of early-stage assets. These include IBB0979, an immunocytokine targeting solid tumors; IBC0966, a dual-action fusion protein (anti-PD-L1 antibody-signal regulatory protein) in clinical development, designed to elicit tumor-specific immune responses; IBD0333, aimed at tumor cells; IAN0982, another oncology candidate; and immunosuppressants ISH0988 and ISH0613, which are being explored for autoimmune conditions. Established in 2018, the company operates from its headquarters in Huzhou, China, and functions as a subsidiary of Sunho Wisdom Investments Limited.
Prezzo delle azioni
$0.81744861
Ultima sincronizzazione: 2026-04-02
Capitalizzazione di mercato
$124.61M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-7.82%
Paese
CN
Scambia Sunho Biologics, Inc. (2898)

Categoria

Healthcare
Ricavi di Sunho Biologics, Inc. (2898)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Sunho Biologics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Sunho Biologics, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH